PEDIATRICS Vol. 85 No. 4 April 1990, pp. 682-689
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dashefsky, B.
Right arrow Articles by Byers, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dashefsky, B.
Right arrow Articles by Byers, C.

Safety, Tolerability, and Immunogenicity of Concurrent Administration of Haemophilus influenzae Type b Conjugate Vaccine (Meningococcal Protein Conjugate) With Either Measles-Mumps-Rubella Vaccine or Diphtheria-Tetanus-Pertussis and Oral Poliovirus Vaccines in 14-to 23-Month-Old Infants

Barry Dashefsky MD1, Ellen Wald MD1, Nancy Guerra CRNP1, and Carol Byers CRNP1

1 From the University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pennsylvania

In 1985, the first capsular polysaccharide (polyribosylribitol-phosphate [PRP]) vaccine for Haemophilus influenzae type b was licensed and recommended for routine use in children between 24 and 60 months of age.1,2 In the United States, approximately 75% to 90% of invasive disease due to H influenzae type b occurs in infants younger than 24 months,1,3 a population for whom H influenzae type b polysaccharide vaccine is inadequately immunogenic and protective. In an effort to enhance the immunogenicity of H influenzae type b polysaccharide vaccine for children in the most susceptible age groups, conjugate vaccines have been developed in which the capsular PRP of H influenzae type b has been bound to a variety of carrier proteins, thereby conferring the vaccines with thymic-dependent attributes.4,5 One such conjugate vaccine, in which the carrier protein is diphtheria toxoid (PRP-D), was licensed in 1987 and has been recommended since 1988 for routine use in children 18 months of age and older.6,7 A second conjugate vaccine, in which an oligosaccharide derivative of H influenzae type b capsular PRP is coupled to CRM197, a nontoxic mutant diphtheria toxin (oligo-CRM), was licensed in 1988 and is a sanctioned alternative to PRP-D.8 Another investigational conjugate vaccine, in which the polysaccharide is linked to the outer membrane protein of Neisseria meningitidis group B (PRP-OMPC), has been demonstrated to be both safe and immunogenic when administered in a two-dose schedule to 2- to 6-month-old infants.9 However, anti-PRP antibody levels decline significantly during the ensuing 10 to 15 months10,11; they rise significantly in response to booster doses of either PRP or PRP-OMPC administered 10 to 15 months after the initial priming doses of PRP-OMPC.11,12




This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
J. Gindler, S. C. Hadler, P. M. Strebel, and J. C. Watson
Recommended Childhood Immunization Schedule: United States 1995
Clinical Pediatrics, February 1, 1995; 34(2): 66 - 72.
[PDF]